Fig. 1From: Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease; ORR, objective response rate; PFS, progression-free survival; OS, overall survivalBack to article page